免疫抑制剂与帕金森病风险
Immunosuppressants and risk of Parkinson disease.
作者信息
Racette Brad A, Gross Anat, Vouri Scott Martin, Camacho-Soto Alejandra, Willis Allison W, Searles Nielsen Susan
机构信息
Department of Neurology Washington University School of Medicine 660 South Euclid Avenue, Campus Box 8111 St. Louis Missouri 63110.
School of Public Health Faculty of Health Sciences University of the Witwatersrand 7 York Road Parktown 2193 South Africa.
出版信息
Ann Clin Transl Neurol. 2018 May 31;5(7):870-875. doi: 10.1002/acn3.580. eCollection 2018 Jul.
Abstract
We performed a population-based case-control study of United States Medicare beneficiaries age 60-90 in 2009 with prescription data (48,295 incident Parkinson disease cases and 52,324 controls) to examine the risk of Parkinson disease in relation to use of immunosuppressants. Inosine monophosphate dehydrogenase inhibitors (relative risk = 0.64; 95% confidence interval 0.51-0.79) and corticosteroids (relative risk = 0.80; 95% confidence interval 0.77-0.83) were both associated with a lower risk of Parkinson disease. Inverse associations for both remained after applying a 12-month exposure lag. Overall, this study provides evidence that use of corticosteroids and inosine monophosphate dehydrogenase inhibitors might lower the risk of Parkinson disease.
摘要
2009年，我们针对美国年龄在60 - 90岁且有处方数据的医疗保险受益人开展了一项基于人群的病例对照研究（48295例帕金森病新发病例和52324例对照），以研究使用免疫抑制剂与帕金森病风险之间的关系。肌苷单磷酸脱氢酶抑制剂（相对风险 = 0.64；95%置信区间0.51 - 0.79）和皮质类固醇（相对风险 = 0.80；95%置信区间0.77 - 0.83）均与较低的帕金森病风险相关。在应用12个月的暴露滞后时间后，两者的反向关联仍然存在。总体而言，本研究提供了证据表明，使用皮质类固醇和肌苷单磷酸脱氢酶抑制剂可能会降低帕金森病的风险。
相似文献
1
Immunosuppressants and risk of Parkinson disease.免疫抑制剂与帕金森病风险
Ann Clin Transl Neurol. 2018 May 31;5(7):870-875. doi: 10.1002/acn3.580. eCollection 2018 Jul.
2
Effects of short-term exposure to air pollution on hospital admissions of young children for acute lower respiratory infections in Ho Chi Minh City, Vietnam.越南胡志明市短期暴露于空气污染对幼儿急性下呼吸道感染住院率的影响。
Res Rep Health Eff Inst. 2012 Jun(169):5-72; discussion 73-83.
3
Groundwater pesticide levels and the association with Parkinson disease.地下水中农药水平及其与帕金森病的关联。
Int J Toxicol. 2015 May-Jun;34(3):266-73. doi: 10.1177/1091581815583561. Epub 2015 May 4.
4
Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus.霉酚酸暴露及补体C3对系统性红斑狼疮中肌苷5'-单磷酸脱氢酶活性的影响。
Ann Clin Biochem. 2017 Jul;54(4):490-494. doi: 10.1177/0004563216667753. Epub 2016 Aug 17.
5
Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.医疗保险D部分实施前后青光眼弱势受益人群中处方药覆盖范围参保情况的变化
JAMA Ophthalmol. 2016 Feb;134(2):212-20. doi: 10.1001/jamaophthalmol.2015.5090.
6
Validation of secondary data sources to identify Parkinson disease against clinical diagnostic criteria.利用二级数据源验证帕金森病与临床诊断标准的符合度。
Am J Epidemiol. 2015 Feb 1;181(3):185-90. doi: 10.1093/aje/kwu326. Epub 2014 Dec 29.
7
Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study.炎症性肠病女性患宫颈异常的风险：一项基于人群的巢式病例对照研究。
Gastroenterology. 2009 Feb;136(2):451-8. doi: 10.1053/j.gastro.2008.10.021. Epub 2008 Oct 15.
8
Associations of depression diagnosis and antidepressant treatment with mortality among young and disabled Medicare beneficiaries with COPD.抑郁诊断和抗抑郁治疗与 COPD 老年和残疾医疗保险受益人的死亡率之间的关联。
Gen Hosp Psychiatry. 2013 Nov-Dec;35(6):612-8. doi: 10.1016/j.genhosppsych.2013.06.005. Epub 2013 Jul 18.
9
Time until incident dementia among Medicare beneficiaries using centrally acting or non-centrally acting ACE inhibitors.使用中枢作用或非中枢作用 ACE 抑制剂的 Medicare 受益人的痴呆事件发生时间。
Pharmacoepidemiol Drug Saf. 2013 Jun;22(6):641-8. doi: 10.1002/pds.3449.
10
Socioeconomic status and outcome following acute myocardial infarction in elderly patients.老年患者急性心肌梗死后的社会经济状况与预后
Arch Intern Med. 2004 May 24;164(10):1128-33. doi: 10.1001/archinte.164.10.1128.
引用本文的文献
1
Neuromodulation influences T lymphocyte calcium signaling and alpha synuclein clearance: implications for Parkinson's disease.神经调节影响T淋巴细胞钙信号传导和α-突触核蛋白清除：对帕金森病的启示。
Front Cell Neurosci. 2025 Jul 18;19:1627305. doi: 10.3389/fncel.2025.1627305. eCollection 2025.
2
Advantages and challenges of using allogeneic vs. autologous sources for neuronal cell replacement in Parkinson's disease: Insights from non-human primate studies.帕金森病中使用异体与自体来源进行神经元细胞替代的优势与挑战：来自非人灵长类动物研究的见解
Brain Res Bull. 2025 May;224:111297. doi: 10.1016/j.brainresbull.2025.111297. Epub 2025 Mar 12.
3
Clinical Trial Highlights: Anti-Inflammatory and Immunomodulatory Agents.临床试验重点：抗炎和免疫调节剂。
J Parkinsons Dis. 2024;14(7):1283-1300. doi: 10.3233/JPD-240353.
4
Update: Protective and risk factors for Parkinson disease.更新：帕金森病的保护和风险因素。
Parkinsonism Relat Disord. 2024 Aug;125:107026. doi: 10.1016/j.parkreldis.2024.107026. Epub 2024 Jun 13.
5
The immune system in Parkinson's disease: what we know so far.帕金森病中的免疫系统：目前我们所知的。
Brain. 2024 Oct 3;147(10):3306-3324. doi: 10.1093/brain/awae177.
6
Lysosomal storage, impaired autophagy and innate immunity in Gaucher and Parkinson's diseases: insights for drug discovery.溶酶体储存、自噬和先天免疫在 Gaucher 和帕金森病中的作用：药物发现的新视角。
Philos Trans R Soc Lond B Biol Sci. 2024 Apr 8;379(1899):20220381. doi: 10.1098/rstb.2022.0381. Epub 2024 Feb 19.
7
Cortistatin as a Novel Multimodal Therapy for the Treatment of Parkinson's Disease.考替司他丁：一种治疗帕金森病的新型多模态治疗方法。
Int J Mol Sci. 2024 Jan 5;25(2):694. doi: 10.3390/ijms25020694.
8
Versatile guardians: regenerative regulatory T cells in Parkinson's disease rodent models.多功能守护者：帕金森病啮齿动物模型中的再生调节性T细胞
Signal Transduct Target Ther. 2023 Nov 20;8(1):430. doi: 10.1038/s41392-023-01681-4.
9
Association Between Use of Any of the Drugs Prescribed in Norway and the Subsequent Risk of Parkinson Disease: A Drug-wide Association Study.挪威处方药物的使用与帕金森病风险的相关性：一项药物广泛相关性研究。
Neurology. 2023 Nov 21;101(21):e2068-e2077. doi: 10.1212/WNL.0000000000207899. Epub 2023 Oct 10.
10
Biologic targets of prescription medications and risk of neurodegenerative disease in United States Medicare beneficiaries.处方药物的生物靶点与美国医疗保险受益人群神经退行性疾病的风险。
PLoS One. 2023 May 17;18(5):e0285011. doi: 10.1371/journal.pone.0285011. eCollection 2023.
本文引用的文献
1
A predictive model to identify Parkinson disease from administrative claims data.一种从行政索赔数据中识别帕金森病的预测模型。
Neurology. 2017 Oct 3;89(14):1448-1456. doi: 10.1212/WNL.0000000000004536. Epub 2017 Sep 1.
2
Observational Studies: Matching or Regression?观察性研究：匹配还是回归？
Biol Blood Marrow Transplant. 2016 Mar;22(3):557-63. doi: 10.1016/j.bbmt.2015.12.005. Epub 2015 Dec 19.
3
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.一水肌酸对帕金森病患者临床进展的影响：一项随机临床试验。
JAMA. 2015 Feb 10;313(6):584-93. doi: 10.1001/jama.2015.120.
4
Colonic inflammation in Parkinson's disease.帕金森病中的结肠炎症。
Neurobiol Dis. 2013 Feb;50:42-8. doi: 10.1016/j.nbd.2012.09.007. Epub 2012 Sep 24.
5
Matching methods for causal inference: A review and a look forward.因果推断的匹配方法：综述与展望
Stat Sci. 2010 Feb 1;25(1):1-21. doi: 10.1214/09-STS313.
6
The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights.糖皮质激素的抗炎和免疫抑制作用：最新进展和机制见解。
Mol Cell Endocrinol. 2011 Mar 15;335(1):2-13. doi: 10.1016/j.mce.2010.04.005. Epub 2010 Apr 14.
7
Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies.α-突触核蛋白从神经元直接转移到星形胶质细胞会导致突触核蛋白病中的炎症反应。
J Biol Chem. 2010 Mar 19;285(12):9262-72. doi: 10.1074/jbc.M109.081125. Epub 2010 Jan 13.
8
A double-blind, delayed-start trial of rasagiline in Parkinson's disease.雷沙吉兰治疗帕金森病的双盲、延迟启动试验。
N Engl J Med. 2009 Sep 24;361(13):1268-78. doi: 10.1056/NEJMoa0809335.
9
Neuroinflammation in Parkinson's disease: a target for neuroprotection?帕金森病中的神经炎症：神经保护的一个靶点？
Lancet Neurol. 2009 Apr;8(4):382-97. doi: 10.1016/S1474-4422(09)70062-6.
10
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.混合谱系激酶抑制剂CEP-1347未能延缓早期帕金森病的残疾进展。
Neurology. 2007 Oct 9;69(15):1480-90. doi: 10.1212/01.wnl.0000277648.63931.c0. Epub 2007 Sep 19.
Zotero 插件